GlassScriptPhysician profile
Frederic Albert Rawlins
NPI 1235450727
$5,460.81
in general payments reported to CMS, 2019-2025
33 companies · $2,190 in 2025
The $2,190 reported for 2025 was more than what 77% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.91 · 2020: $15.79 · 2021: $15.80 · 2023: $227 · 2024: $2,926 · 2025: $2,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,853 · Education: $490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,852.54 |
| Education | $489.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,248.99 | 2023-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $511.04 | 2024-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $452.72 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $395.65 | 2023-2025 | Purified Cortrophin Gel |
| United Therapeutics Corporation | $298.52 | 2023-2025 | Tyvaso, Tyvaso |
| Regeneron Healthcare Solutions, INC. | $266.30 | 2024-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $258.51 | 2024-2025 | Uptravi, Opsumit |
| Mallinckrodt Hospital Products INC. | $257.69 | 2024-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.94 | 2019-2025 | Ofev |
| Amgen INC. | $176.64 | 2023-2025 | Tezspire |
| Insmed, INC. | $157.36 | 2024-2025 | Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $157.03 | 2024-2025 | Glassia |
| Inspire Medical Systems, INC. | $118.14 | 2024-2025 | Inspire |
| Harmony Biosciences LLC | $115.49 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.93 | 2024-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $97.10 | 2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $76.91 | 2023-2024 | |
| Verona Pharma, INC. | $73.33 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $65.49 | 2024 | Prolastin-C Liquid |
| Philips North America LLC | $61.04 | 2024-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Axsome Therapeutics, INC. | $55.67 | 2025 | Sunosi |
| Vifor Pharma, INC. | $52.92 | 2024-2025 | Veltassa |
| Electromed, INC. | $44.39 | 2024-2025 | Smartvest |
| Viatris Specialty LLC | $39.73 | 2025 | Yupelri |
| Chiesi USA, INC. | $31.59 | 2020-2021 | |
| Inogen, INC. | $30.37 | 2024 | |
| Merck Sharp & Dohme LLC | $24.00 | 2024 | |
| Tempus Ai, INC | $21.83 | 2025 | Xt Cdx |
| Braemar Manufacturing, LLC | $17.14 | 2019 | |
| Sunovion Pharmaceuticals INC. | $16.05 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.38 | 2019 | |
| Pulmonx Corporation | $13.55 | 2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Pfizer INC. | $13.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederic Rawlins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.